|  Accomplia Side Effects
In the liver the Fettsäuresynthese is increased by blockade of the CB1-Rezeptoren, in the muscle the glucose admission increased and in the fatty tissue increases Adiponektin formed, which works antiinflammatorisch and which insulin sensitivity increases.
Change of the kardiometabolischen factors of risk under Acomplia®
All available studies (under it RIO North America, RIO Europe, RIO of Lipids, RIO diabetes) occupy a clearer improvement of the kardiometabolischen factors of risk, thus Professor Dr. Stefan Jacob, for the 6600 patients treated with Rimonabant Villingen Schwenningen. Thus the studies describe not only a reduction of the waist extent (as clinically detectable expression of the intraabdominalen quantity of grease), but also a reduction of the insulin resistance (HOMA-IR) as well as a clear improvement of glykämischen control with patients with diabetes mellitus type 2. In the RIO diabetes study the absolute difference amounted to with the HbA1c-Wert between the Plazebo and the Rimonabant group 0.7% and was clinically very much pronounced thereby with an initial value of 7,3%. The side effects were independent of the kind of the antidiabetischen Begleitbehandlung. Further in all studies consistently an increase of the HDL Cholesterinwerte is reached around approx. 8 to 10% opposite Plazebo; this is a relevant contribution for the reduction of the cardiovascular risk, shows nevertheless epidemiological studies that an increase of the HDL is associated around 1% with a reduction of the vascular events around 2 to 3%.
• significant reduction of waist extent and weight
• significant improvement of the kardiometabolischen profile with:
• increased HDL Cholesterin and reduced triglyceride mirror
• improved insulin sensitivity (HOMA)
• a clinically relevant improvement of HbA1c with patients with Typ-2-Diabetes, which was treated with an oral Antidiabetika Monotherapie
• 43% of the patients reached a HbA1c-Wert < 6=""> • a significant reduction of the portion of the patients with metabolic syndrome
• einer signifikanten Reduktion des Anteils der Patienten mit Metabolischem Syndrom
|
Acomplia
Menu 
